Copyright
©The Author(s) 2019.
World J Hepatol. Jan 27, 2019; 11(1): 65-73
Published online Jan 27, 2019. doi: 10.4254/wjh.v11.i1.65
Published online Jan 27, 2019. doi: 10.4254/wjh.v11.i1.65
HBsAg | Anti-HBs | Viremia | cccDNA | |
Functional cure | - | + | - | + |
Complete cure | - | + | - | - |
Patient | Date start Tx | Chang in child class on Tx | Date HCC Dx | Years on anti-HBV Tx at HCC DX | Years with HBV DNA (-) | Age (yr) at HCC Dx | Size (cm) and site of HCC | HBV DNA at HCC Dx | Anti-HBV Tx | Status |
1 | 4/1998 | B→A | 7/2007 | 9.3 | 3.41 | 53 | 1.1 Junction | UD | LAM + TDF | Alive |
2 | 6/2002 | A→A | 8/2007 | 5.2 | 4.7 | 70 | 1.0 Rt | UD | LAM + TDF | Alive |
3 | 1/1998 | B→A | 3/2008 | 10.2 | 8.2 | 68 | 2.8 × 2.5 | UD | LAM + TDF | Dead |
4 | 5/1998 | A→A | 2/2008 | 9.8 | 6.7 | 76 | 1.8 × 0.9 Lt | UD | LAM + TDF | Alive |
5 | 7/2004 | B→B | 9/2009 | 5.2 | 4.7 | 52 | 3.9 Rt | UD | LAM + TDF | Alive |
6 | 7/2001 | B→B | 9/2010 | 9.2 | 4.1 | 54 | 2.8 Rt | UD | LAM + TDF | Dead |
7 | 2/2004 | A→A | 6/2013 | 9. 3 | 7.7 | 57 | 2.5 Lt med | UD | TDF | Dead |
8 | 2/1996 | A→A | 7/2013 | 17.4 | 9.7 | 73 | 1.6 × 1.4 Rt | UD | TDF | Dead |
9 | 8/1997 | A→A | 6/2014 | 16.8 | 5.9 | 54 | 2.2 × 1.9 Lt lat | UD | ETV | Alive |
10 | 5/1996 | A→A | 10/2014 | 18.4 | 10.4 | 74 | 3.4 Rt | UD | LAM + TDF | Dead |
11 | 2/2000 | A→A | 4/2015 | 15.2 | 12.4 | 62 | 3.4 × 3.4 Rt | UD | TDF | Alive |
12 | 2/2000 | B→A | 5/2015 | 15.3 | 12.2 | 65 | 3.8 Rt | UD | TDF | Alive |
- Citation: Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73
- URL: https://www.wjgnet.com/1948-5182/full/v11/i1/65.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i1.65